CSBio CSBio

X
[{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Timber Pharmaceuticals\u2019 Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreement for Pascomer\u00ae (TMB-002) in Europe","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"NEW ZEALAND","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AFT Pharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe.

            Lead Product(s): Sirolimus

            Therapeutic Area: Dermatology Product Name: Pascomer

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Timber Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 17, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY